Actively Recruiting
Fructose and Liver Diseases in Youth: Help Them FLY
Led by University of Alberta · Updated on 2024-10-09
70
Participants Needed
1
Research Sites
504 weeks
Total Duration
On this page
Sponsors
U
University of Alberta
Lead Sponsor
A
Alberta Health services
Collaborating Sponsor
AI-Summary
What this Trial Is About
Obesity has been increasing all over the world. This has lead to a significant increase of a liver disease in children called non-alcoholic fatty liver disease (NAFLD). NAFLD is a liver disease that ranges from excess fat being stored in the liver to an inflamed and fatty liver with fibrosis to cirrhosis. NAFLD is thought to be caused by changes in energy, fat and carbohydrate metabolism induced by diets high in in processed foods. Sugary (especially high fructose corn syrup or HFCS) and fatty foods in processed foods have been shown to produce more insulin resistance, a factor that is thought to cause a fatty liver. Currently the main treatment for NAFLD is weight loss. However, it unknown the best way to achieve this. The investigator has shown previously that adolescents with NAFLD eat a lot of fatty and sugary foods, and that when they decrease the amount of foods they eat that contain HFCS, experience some improvements in insulin resistance and liver dysfunction even when they don't lose weight. The plan is to compare and contrast how two different diets (high vs low HFCS containing diets) may affect how much fat gets deposited in the liver and whether or not a lower diet in HFCS can help decrease liver damage in adolescents with NAFLD.
CONDITIONS
Official Title
Fructose and Liver Diseases in Youth: Help Them FLY
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Obese boys and girls aged 12 to 18 years (Tanner Stage III-V) with clinically diagnosed non-alcoholic fatty liver disease (NAFLD)
You will not qualify if you...
- History of primary liver diseases causing steatohepatitis such as Wilson disease, metabolic disorders, or viral hepatitis
- Diagnosis of Type 2 Diabetes or use of insulin
- Use of medications causing liver fat buildup (methotrexate, corticosteroids, valproic acid, statins)
- Evidence of bridging liver fibrosis
- Significant history of smoking or alcohol use
- Participation in an active weight loss program or prior bariatric surgery for obesity
- Presence of a cardiac pacemaker or metal pins (contraindications for MRI/MRS)
- Pregnancy or known pregnancy in females of childbearing potential
- Significant developmental delay or serious health conditions preventing participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Clinical Research Unit, University of Alberta
Edmonton, Alberta, Canada, T6G 0K2
Actively Recruiting
Research Team
D
Diana R Mager, PhD RD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here